From our survey
Most people are not against ketamine therapy, they are unsure
Our survey found answers bunched in the cautious middle, and the same people named what would move them: their own doctor and coverage.
Put this question to a general population and the answers do not split into two camps. They bunch in the middle.
We commissioned a survey of 443 adults, put a plain description of ketamine-based care for depression or PTSD in front of them, and recorded their first-glance feelings. The largest group was neither for it nor against it. It was cautious but open. The smallest group, by a wide margin, said no.
What we asked
One question, five options, and no setup steering anyone. Each respondent read the phrase and picked the reaction nearest their own. Pollfish carried it to members of its consumer panel, and fieldwork wrapped up June 23, 2026. Every figure below comes from the panel's final validated data.
What came back
Here is the full spread of those first reactions, in the order our respondents ranked them. Cautious but open took 34 percent. Skeptical took 21 percent. Two answers tied at 18 percent: never heard of it, and hopeful or curious. Negative came last at 9 percent.
Add cautious but open to hopeful or curious and 51 percent of the sample leans toward yes, while a flat no is 9 percent. Between them are the 21 percent who called themselves skeptical, a conditional answer rather than a closed one, and the 18 percent who had not met the idea before we described it.
Most of this sample is open to ketamine therapy and fewer than one in ten is against it. The obstacle in this category is not opposition. It is uncertainty.
One caveat belongs beside that sentence. "Never heard of it" does not mean open, and we did not fold it in to get a bigger number. Those people hold no position, and someone with no position can land anywhere once informed. Counting them as quiet demand would be the easiest flattering mistake in this dataset, so we are naming it instead of making it.
What the same people said would move them
The reaction question takes the temperature of the room. Other questions measured what would change it, and the answers were lopsided.
When we asked whose recommendation would most likely get them to try this, 74 percent chose their own doctor. Close friends and family trailed at 18 percent. Someone from the military or first responder world whom they follow online drew 4 percent, paid ads 2 percent, and podcast voices 1 percent.
Institutional signals sorted the same way. Among respondents, 59 percent said FDA approval would settle or strongly sway their choice, and 65 percent said the same of insurance coverage, including 22 percent for whom coverage alone would decide it.
Beneath all of it is an information floor lower than most people in this field assume. Spravato is the esketamine nasal spray that carries FDA approval for depression resistant to standard treatment, and 73 percent of our respondents drew a total blank on it. Another 21 percent recognized it only as a name with nothing behind it. The 6 percent who could describe it round out a snapshot of the public, not of doctors. We did not survey physicians, and nothing here speaks to what clinicians know.
Why caution is the reasonable position
The cautious 34 percent look less like a messaging problem than like sound instinct. The word ketamine currently covers at least three things with three regulatory stories, and anyone who has not had that explained is right to hold back.
Esketamine, sold as Spravato, is the approved one. The patient sprays it at a certified clinic under a provider's eye, then waits through a monitoring period before leaving. It is never sent home, and the patient does not drive afterward.
Generic ketamine by IV at a clinic is a different arrangement. Ketamine is a long-approved anesthetic, and using it for depression is off label. That is legal and ordinary in medicine, but this particular use has not been through the FDA review that esketamine has, and the difference should be stated plainly. If you want to see how the approved, supervised route is actually delivered, Brain Recovery Centers describes what a Spravato session involves.
Then there is ketamine for home use, typically a dissolving tablet prescribed over video and taken alone: a third thing, and the grayest. Whatever reassurance "supervised" and "certified setting" offer, they do not describe it.
These are not three shades of one product. Someone who answers cautious but open and then asks which one you mean is not being difficult. They are asking the exact question this survey says most people need answered.
Who was asked, and what this cannot tell you
This was a general population read: adults 18 to 64 recruited from a consumer panel, not screened patients or people already shopping for depression care. That suits this question, because it captures how ordinary people react before they need anything. It also means these are not the views of anyone in treatment. Three limits travel with every number above.
- These are top-line percentages only. We cite no cross-tabs here, so any sentence that begins "among respondents who" and slices the sample into a subgroup is unsupported, however plausible it sounds.
- These are stated preferences. Stated reasons and real exam-room decisions are cousins, not twins.
- This is market research about a decision, not clinical evidence or medical advice. It cannot show that a treatment works for anyone; suitability is for a clinician who knows the person's history.
What the survey supports is narrow and useful. Most adults in this sample are not against ketamine therapy, very few are, and the big group in the middle is waiting on the same three things: a doctor they trust, a regulator, and a payer.
One thing matters more than any percentage here. If life feels unsurvivable right now, or you keep circling back to the idea that your family would manage better without you, the Lifeline is a call or text away at 988, from any state and at any hour. It is free and confidential, and a hard night is reason enough to use it.
Methodology
This publisher commissioned the study and bore its cost. Pollfish's consumer panel yielded 443 completes from adults 18 to 64 living in Ohio, Iowa, Oklahoma, Wisconsin, Missouri, and five more Midwest states; the survey closed June 23, 2026. Results here are top-line only, without subgroup analysis. On questions that allowed several answers, the shares total more than 100. Pollfish completed its validation before we reported any of it.